Sign up to save your podcasts
Or
Share Pluses and minuses of the weight-loss drug bonanza
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Pluses and minuses of the weight-loss drug bonanza
Obesity treatments made by Novo Nordisk and Eli Lilly have spawned a healthcare revolution, with sales set to hit $150 bln by 2031. In this episode of The Big View, Peter Thal Larsen talks to Breakingviews Associate Editor Aimee Donnellan about their origins – and their impact.
Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By Reuters
4.4
2525 ratings
Obesity treatments made by Novo Nordisk and Eli Lilly have spawned a healthcare revolution, with sales set to hit $150 bln by 2031. In this episode of The Big View, Peter Thal Larsen talks to Breakingviews Associate Editor Aimee Donnellan about their origins – and their impact.
Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More shows like The Big View
View all
Economist Podcasts
4,183 Listeners
Trumponomics
353 Listeners
Viewsroom
46 Listeners
Foreign Policy Live
606 Listeners
FT News Briefing
661 Listeners
Behind the Money
226 Listeners
The Intelligence from The Economist
2,550 Listeners
The World in Brief from The Economist
1,071 Listeners
The Rachman Review
138 Listeners
The Foreign Affairs Interview
442 Listeners
Reuters World News
279 Listeners
Unhedged
179 Listeners
The Economics Show
148 Listeners
Reuters Econ World
28 Listeners
Swamp Notes
26 Listeners